Overview

A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is a dose ranging study to evaluate the safety and efficacy of baricitinib in the treatment of participants with mild to moderate diabetic kidney disease.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Incyte Corporation